knowledge -WSS

knowledge

author：leisure time 2025-09-28 21:58:51 - browse：7

Teleflex announced plans on Wednesday to acquire Palette Life Sciences, the maker of a slate of gel-based products treating urological disorders. The vascular device manufacturer will pay $600 million upfront, and plans to use Palette’s portfolio to treat more urinary tract and reproductive health conditions.

Palette will bring Teleflex an extra $56 million in sales, the company estimated in a press release. Teleflex develops a range of devices, but makes the most money from vascular products like catheters. The company offers just one urological treatment: the UroLift system to relieve an enlarged prostate. With Palette, it will gain five more treatments all built from hyaluronic acid, a stretchy material that’s meant to last longer in the human body.

Palette’s highest-revenue device is Barrigel, which helps protect the rectum from harsh radiation administered to prostate cancer patients. It eases symptoms like bladder inflammation, bleeding, and diarrhea. The device received FDA clearance in May 2022 through the 510(k) process, which allowed Palette to claim the product was equivalent to a rectal radiation protector sold by Boston Scientific. Boston Scientific has sold that device since 2018, when it acquired it by buying the startup Augmenix for $500 million.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： The high cost of giving birth even with insurance
Next article： The Readout: Gilead, Bernie Sanders, and other pharma news

Wikipedia

WSS

Gilead might be held responsible for not developing a drug

Gilead might be held responsible for not developing a drug

KalVista pill reduced swelling 'attacks' caused by genetic disease

Detailed data confirm benefits, risks of Eli Lilly's Alzheimer's drug

Doctors find melanoma drugs effective against rare brain cancer

Sanders adds drug shortage policies to pandemic preparedness bill

hotspot

knowledge

focus

How one medical school became remarkably diverse

Whistleblower: Blue Cross Blue Shield evaded $170 million in taxes

Sports medicine is finally prioritizing gender equality

Biogen Alzheimer’s drug launch off to slow start

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

A ‘polypill’ could sharply reduce cardiovascular disease in the U.S.

Duchenne breakthrough therapy leaves behind pioneering families

Why hospitals are withdrawing from US News rankings

As demand for Covid shots wanes, Moderna seeks its next success

Custom gene therapy hints at new path for rare disease treatments

hotspot

Custom gene therapy hints at new path for rare disease treatments

For Medicare Advantage, Democrats want stronger protections around AI

How dance can help nurses traumatized by Covid

Google and Epic fight stronger regulation of AI in health care

Google and Epic fight stronger regulation of AI in health care

A ‘polypill’ could sharply reduce cardiovascular disease in the U.S.

focus

Wikipedia

entertainment

explore